在注册分类改革后,中国批准的创新药物:当前的状态,差异和挑战
Xingyue Zhu1,2, Die Xiao1
1School of Medicine and Health Management, Guizhou Medical University, Guiyang, Guizhou, China.
Clinical pharmacology and therapeutics
|October 11, 2025
概括
中国中国中国中国.
科学领域:
- 制药科学 制药科学
- 药物监管 药物监管 药物监管
- 临床研究 临床研究
背景情况:
- 中国国家医疗产品管理局 (NMPA) 在2016年改革了药物注册规则,将创新药物定义为国内和全球市场新鲜的药物.
- 这一改革旨在促进国内制药创新,并与国际标准保持一致.
研究的目的:
- 系统地评估中国改革后批准的创新药物的特性.
- 分析药物类型,治疗领域和创新药物的监管途径的趋势.
主要方法:
- 一项横截面研究分析了NMPA在2024年之前批准的创新型小分子,生物制剂和中国药物.
- 从NMPA的开放数据库中提取的数据,包括药物信息和关键试验特征.
- 纳入标准规定了小分子与生物制剂和中国药物的不同申请提交时间表.
主要成果:
- 167种创新药物获得批准:58.1%是小分子,31.1%是生物制品,10.8%是中药.
- 国内药品占86.8%,显示了从2018年到2024年的增长.
- 瘤学是占主导地位的领域 (43.7%),特别是生物 (55.8%). 大多数瘤药物 (90.4%) 使用代用终点.
- 加快程序加速了开发,但审查时间往往超过了目标. 中国药品面临的监管灵活性较少.
结论:
- 中国的制药创新正在增长,国内的小分子和生物制品领先.
- 瘤学仍然是一个关键的重点,经常利用代用终点来获得更快的批准.
- 进一步投资于差异化疗法,金融激励和改善监管能力对于全球竞争力至关重要.
更多相关视频
相关概念视频
01:26FDA Approved Drugs: Changes to Approved Drugs
214
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
214
01:25Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
01:28Drug Products: Biologics, Biosimilars and Interchangeables
208
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
208
01:25Drug Classes and Categories
2.7K
Drugs can be classified according to their chemical composition or their intended therapeutic application. For instance, anti-infective agents that possess the ability to eliminate pathogens or suppress their growth and reproduction can be grouped based on the organisms they target or their chemical structure. Furthermore, drugs can be divided into prescription, nonprescription, or controlled substances. Prescription medications, such as antibiotics, require oversight from a licensed healthcare...
2.7K
01:11Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
01:03Drug Control Governance: Regulatory Bodies and Their Impact
457
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
457